Search research articles
Contact Us
Filters
Showing results (11-20 of 15) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 15 results.
Journal of Materials Chemistry. B
|
April 8, 2020
One-pot direct synthesis for multifunctional ultrasmall hybrid silica nanoparticles
Vu-Long Tran, Vivek Thakare, Fabien Rossetti, et al.
Theranostics
|
October 14, 2020
A snake toxin as a theranostic agent for the type 2 vasopressin receptor
Laura Droctové, Manon Lancien, Vu Long Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma
Elena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer
|
June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
The British Journal of Radiology
|
September 19, 2018
AGuIX
François Lux, Vu Long Tran, Eloïse Thomas, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 15) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 15 results.
Journal of Materials Chemistry. B
|
April 8, 2020
One-pot direct synthesis for multifunctional ultrasmall hybrid silica nanoparticles
Vu-Long Tran, Vivek Thakare, Fabien Rossetti, et al.
Theranostics
|
October 14, 2020
A snake toxin as a theranostic agent for the type 2 vasopressin receptor
Laura Droctové, Manon Lancien, Vu Long Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma
Elena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer
|
June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Kristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
The British Journal of Radiology
|
September 19, 2018
AGuIX
François Lux, Vu Long Tran, Eloïse Thomas, et al.
Page
of 2